SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that the management team will participate in four upcoming investor conferences in November.

Stifel 2023 Healthcare Conference
Fireside Chat: Tuesday, November 14^th at 1:15 pm ET
One-on-one meetings: November 14^th, 2023
Presenter: Dr. Kevin Xie, Chief Financial Officer
Location: New York

Jefferies London Healthcare Conference
Fireside Chat: Wednesday, November 15^th at 11:30 am GMT / 6:30 am ET
One-on-one meetings: November 15^th and 16^th, 2023
Presenter: Dr. Kevin Xie, Chief Financial Officer
Location: London

Piper Sandler 35^th Annual Healthcare Conference
Presentation: Tuesday, November 28^th at 12:00 pm
One-on-one meetings: November 28^th, 2023
Presenter: Dr. Kevin Xie, Chief Financial Officer
Location: New York

6th Annual Evercore ISI HealthCONx Conference
Presentation: Wednesday, November 29^th at 9:35 am ET
One-on-one meetings: November 29^th and 30^th, 2023
Presenter: Dr. Kevin Xie, Chief Financial Officer
Location: Miami

Available webcasts of the presentations will be posted on the News and Events section of the Company's website. A replay of the webcast will be available for 90 days following the event. For more information, please visit ir.gracellbio.com.

About Gracell
Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies for the treatment of cancers and autoimmune diseases. Leveraging its innovative FasTCAR and TruUCAR technology platforms and SMART CART™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost, and lack of effective CAR-T therapies for solid tumors and autoimmune diseases. The lead candidate BCMA/CD19 dual-targeting FasTCAR-T GC012F is currently being evaluated in clinical studies for the treatment of multiple myeloma, B-NHL and systemic lupus erythematosus (SLE). For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

Media contact
Marvin Tang
marvin.tang@gracellbio.com

Investor contact
Gracie Tong
gracie.tong@gracellbio.com